WHAT IS CLAIMED IS:

1. A method for treating or preventing gastritis in a subject, comprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin.

2. A method for treating or preventing gastric ulceration in a subject, comprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin.

3. A method of treating or preventing pain, fever, inflammation, arthritis, hypercoagulability, or other condition for which a non-steroidal anti-inflammatory agent would be indicated, comprising administering to subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin, and a therapeutically effective amount of a non-steroidal anti-inflammatory agent.

4. A method of enhancing the analgesic activity of a non-steroidal anti-inflammatory drug in a subject, comprising administering an amylin or an amylin agonist along with said non-steroidal anti-inflammatory drug, wherein said amylin agonist is not a calcitonin.

5. The method according to any of claims 1-4, wherein said subject is human.

6. The method according to any of claims 1-4, wherein said amylin or amylin agonist is administered by a route selected form the group consisting of nasal, oral, pulmonary, transdermal, and buccal administration.

7. The method according to any of claims 1-4 wherein said amylin agonist is selected from the group consisting

of $^{18}Arg^{25,28}$Pro-h-amylin, des-$^{1}Lys^{18}Arg^{25,28}$Pro-h-amylin, $^{18}Arg^{25-28,29}$Pro-h-amylin, des-$^{1}Lys^{18}Arg^{25,28,29}$Pro-h-amylin, $^{25,28-29}$Pro-h-amylin, des-$^{1}Lys^{25,28,29}$Pro-h-amylin, $^{25}Pro^{26}Val^{28,29}$Pro-h-amylin, $^{23}Leu^{25}Pro^{26}Val^{28,29}$Pro-h-amylin, $^{23}Leu^{25}Pro^{26}Val^{28}$Pro-h-amylin, des-$^{1}Lys^{23}Leu^{25}Pro^{26}Val^{28}$Pro-h-amylin, $^{18}Arg^{23}Leu^{25}Pro^{26}Val^{28}$Pro-h-amylin, $^{18}Arg^{23}Leu^{25,28,29}$Pro-h-amylin, $^{18}Arg^{23}Leu^{25,28}$Pro-h-amylin, $^{17}Ile^{23}Leu^{25,28,29}$Pro-h-amylin, $^{17}Ile^{25,28,29}$Pro-h-amylin, des-$^{1}Lys^{17}Ile^{23}Leu^{25,28,29}$Pro-h-amylin, $^{17}Ile^{18}Arg^{23}$Leu-h-amylin, $^{17}Ile^{18}Arg^{23}Leu^{26}Val^{29}$Pro-h-amylin, $^{17}Ile^{18}Arg^{23}Leu^{25}Pro^{26}Val^{28,29}$Pro-h-amylin, $^{13}Thr^{21}His^{23}Leu^{26}Ala^{28}Leu^{29}Pro^{31}Asp$-h-amylin, $^{13}Thr^{21}His^{23}Leu^{26}Ala^{29}Pro^{31}Asp$-h-amylin, des-$^{1}Lys^{13}Thr^{21}His^{23}Leu^{26}Ala^{28}Pro^{31}Asp$-h-amylin, $^{13}Thr^{18}Arg^{21}His^{23}Leu^{26}Ala^{29}Pro^{31}Asp$-h-amylin, $^{13}Thr^{18}Arg^{21}His^{23}Leu^{28,29}Pro^{31}Asp$-h-amylin, and $^{13}Thr^{18}Arg^{21}His^{23}Leu^{25}Pro^{26}Ala^{28,29}Pro^{31}Asp$-h-amylin.

8. The method according to any of claims 1-4, wherein said amylin agonist is ^{25,28,29} Pro-h-amylin.

9. The method according to any of claims 1 or 2, wherein said gastritis or gastric ulceration is associated with the administration of a non-steroidal anti-inflammatory drug.

10. The method according to any of claims 3 or 4 wherein said non-steroidal anti-inflammatory agent is selected from the group consisting of salicylate, phenylbutazone, indomethacin, acetominophen, phenacetin, naproxen and ibuprofen.

11. A pharmaceutical composition comprising (1) an amylin or an amylin agonist, or a pharmaceutically acceptable salt thereof, wherein said amylin agonist is not

a calcitonin, and (2) a non-steroidal anti-inflammatory agent, in a pharmaceutically acceptable carrier and dose.

12. The pharmaceutical composition according to claim 11, wherein said non-steroidal anti-inflammatory agent is selected from the group consisting of salicylate, phenylbutazone, indomethacin, acetominophen, phenacetin, naproxen, and ibuprofen.